Another study showed that after 12 months, patientswith type 2 diabetes who received glucagon-like peptide-1 (GLP-1) receptoragonists and SGLT-2i had strain improvements from –16 ± 4% to –18.4± 4.7% (p < 0.05) [18]. This evidence concerns the gene GCG and type 2 diabetes mellitus.